Angeliki Giannopoulou

Angeliki Giannopoulou

Auto-generated profile, based on publicly available information

Angeliki Giannopoulou

St. John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2025 in Archives of Dermatological Research
Verified
Journal Article
Open access
PDF file
KAKhalid M. A. Ahmed
Khalid M. A. Ahmed
YKYasmeena Abdelall Kozaa
Yasmeena Abdelall Kozaa
MAMohammad Taleb Abuawwad
Mohammad Taleb Abuawwad
AAAlaa I. Al-Najdawi
Alaa I. Al-Najdawi
YMYomna W. Mahmoud
Yomna W. Mahmoud
AGAngeliki Giannopoulou
Angeliki Giannopoulou
This study evaluates the efficacy and safety of the combined microneedling (CMNT) with minoxidil versus minoxidil monotherapy for the treatment of androgenetic alopecia (AGA), with a focus on the impact of microneedling parameters on treatment outcomes. We conducted a systematic review and meta-analysis (PROSPERO: CRD42024594487) of randomized controlled trials (RCTs) comparing CMNT versus minoxidil alone for AGA, following PRISMA guidelines. A comprehensive search across six databases was performed up to September 8, 2024. We identified 12 RCTs involving 631 AGA patients, with a total of 11 RCTs included in the meta-analyses. CMNT significantly improved hair count compared to minoxidil monotherapy (SMD 1.32, 95% CI 0.73–1.92, p < 0.01), with substantial heterogeneity (I² = 88%, p < 0.01). Subgroup analyses indicated no significant effect of microneedling (MN) depth (≤ 1 mm vs. >1 mm), duration (≤ 12 weeks vs. >12 weeks), or technique(device) (electrodynamic vs. rolling) on hair count outcomes. Additionally, A meta-analysis of six RCTs demonstrated a significant improvement in hair diameter with CMNT (SMD 0.34, 95% CI 0.11–0.58; p < 0.01), with no observed heterogeneity (I² = 0%). Investigators and patient’s self-assessment scores were also improved. Adverse events were more frequent with CMNT (74 vs. 59 events), however they were generally considered mild or self-limiting. CMNT significantly enhances hair count and diameter in AGA patients with mild adverse events. MN parameters including depth, duration, and technique variations did not significantly affect hair count outcome, suggesting microneedling as a promising adjunctive AGA treatment.